Seres Therapeutics announced a significant workforce reduction. The company plans to cut its headcount by 30%. It will also stop investing in its SER-155 phase 2 study. Operational focus will shift to high-value earlier-stage programs. This follows a 25% workforce reduction just months prior.
https://www.biopharmadive.com/news/seres-layoffs-restructuring-microbiome-immune-disease/812079/